Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results
- None.
- None.
Operating Highlights
We officially activated the first clinical trial site with Mayo Clinic and are currently screening patients in the third quarter of 2023. We have contracted with IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage our first clinical trial.
"The initiation of our first clinical study for Cellspan Esophageal Implant (CEI) marked an important milestone for HRGN," said Jerry He, Chairman and CEO of HRGN. "Our numerous preclinical studies and first-in-human E-IND study have demonstrated our technology as an effective platform for tubular organ regeneration. We look forward to testing CEI in the trial as we further our understanding of its potential benefits for patients."
In the second quarter of 2023, the Company's subsidiary in
The Consumer Health business will include a broad range of products focused on anti-aging dietary supplements. The Company plans to start selling anti-aging supplements through the
"The Consumer Health business is a great way to generate additional revenue and operating cash flow from
Summary of Financial Results
For the three months ended June 30, 2023, the Company reported a net loss of
For the six months ended June 30, 2023, the Company reported a net loss of
Balance Sheet and Cash and Cash Equivalents
At June 30, 2023, the Company had operating cash and short-term investments on-hand as of
During the six-month period ended June 30, 2023, the Company used net cash in operations of
About Harvard Apparatus Regenerative Technology, Inc.
We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient's own organs or permanent artificial implants.
We conducted the world's first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Denis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube.
HRGN has 13 issued
For more information, please visit www.hregen.com and connect with the Company on LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; development expectations and regulatory approval of any of the Company's products, by the
Investor Relations Contacts
Joseph Damasio
Chief Financial Officer
774-233-7330
jdamasio@hregen.com
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. | ||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||
(In thousands, except par value and share data) | ||||||||
June 30, | December 31, | |||||||
2023 | 2022 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 2,140 | $ | 1,241 | ||||
Short-term investments | 2,523 | — | ||||||
Prepaid research and development | 259 | 274 | ||||||
Prepaid expenses and other current assets | 79 | 79 | ||||||
Total current assets | 5,001 | 1,594 | ||||||
Property, plant and equipment, net | 39 | 49 | ||||||
Right-of-use assets, net | 135 | 147 | ||||||
Deferred financing costs | 544 | 610 | ||||||
Other long-term assets | 62 | — | ||||||
Total assets | $ | 5,781 | $ | 2,400 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 372 | $ | 682 | ||||
Accrued and other current liabilities | 1,476 | 582 | ||||||
Operating lease liability, current | 119 | 99 | ||||||
Total current liabilities | 1,967 | 1,363 | ||||||
Operating lease liability, net of current portion | 18 | 48 | ||||||
Total liabilities | 1,985 | 1,411 | ||||||
Commitments and contingencies | ||||||||
Series E convertible preferred stock, par value | — | 4,180 | ||||||
Stockholders' equity (deficit): | ||||||||
Common stock, par value | 139 | 122 | ||||||
Additional paid-in capital | 92,172 | 79,698 | ||||||
Accumulated deficit | (88,515) | (83,011) | ||||||
Total stockholders' equity (deficit) | 3,796 | (3,191) | ||||||
Total liabilities and stockholders' equity (deficit) | $ | 5,781 | $ | 2,400 |
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(Unaudited) | ||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
June 30, | June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | $ | 1,566 | $ | 326 | $ | 2,075 | $ | 629 | ||||||||
Selling, general and administrative | 1,085 | 1,049 | 3,463 | 2,951 | ||||||||||||
Total operating expenses | 2,651 | 1,375 | 5,538 | 3,580 | ||||||||||||
Operating loss | (2,651) | (1,375) | (5,538) | (3,580) | ||||||||||||
Other income, net: | ||||||||||||||||
Sublease income | — | 32 | — | 61 | ||||||||||||
Other income (expense), net | 37 | (2) | 34 | (3) | ||||||||||||
Total other income, net | 37 | 30 | 34 | 58 | ||||||||||||
Net loss | (2,614) | (1,345) | (5,504) | (3,522) | ||||||||||||
Preferred stock dividends | 3 | (18) | (77) | (18) | ||||||||||||
Net loss attributable to common stockholders | $ | (2,611) | $ | (1,363) | $ | (5,581) | $ | (3,540) | ||||||||
Basic and diluted net loss per share | $ | (0.19) | $ | (0.12) | $ | (0.43) | $ | (0.32) | ||||||||
Weighted average common shares, basic and diluted | 13,785,657 | 11,230,525 | 13,000,211 | 10,996,996 | ||||||||||||
HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
(Unaudited) | ||||||||
(In thousands) | ||||||||
2023 | 2022 | |||||||
Six Months Ended | ||||||||
June 30, | ||||||||
2023 | 2022 | |||||||
OPERATING ACTIVITIES | ||||||||
Net loss | $ | (5,504) | $ | (3,522) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Share-based compensation expense | 2,319 | 512 | ||||||
Depreciation | 23 | 27 | ||||||
Change in fair value of warrant liability | — | (2) | ||||||
Changes in operating assets and liabilities: | ||||||||
Prepaid research and development | 15 | — | ||||||
Prepaid expenses and other current assets | — | 198 | ||||||
Deferred financing costs | 66 | (173) | ||||||
Other long-term assets | (62) | — | ||||||
Accounts payable | (310) | 823 | ||||||
Accrued and other current liabilities | 894 | 483 | ||||||
Net cash used in operating activities | (2,559) | (1,654) | ||||||
INVESTING ACTIVITIES | ||||||||
Purchases of short-term investments | (2,523) | — | ||||||
Purchases of property, plant, and equipment | (11) | (8) | ||||||
Net cash used in investing activities | (2,534) | (8) | ||||||
FINANCING ACTIVITIES | ||||||||
Proceeds from issuance of common stock | 5,992 | 5,060 | ||||||
Net cash provided by financing activities | 5,992 | 5,060 | ||||||
Net increase in cash and cash equivalents | 899 | 3,398 | ||||||
Cash and cash equivalents at the beginning of the year | 1,241 | 1,292 | ||||||
Cash and cash equivalents at the end of the period | $ | 2,140 | $ | 4,690 | ||||
Supplemental disclosure of non-cash activities: | ||||||||
Settlement of contingency matter | $ | — | $ | (3,250) | ||||
Settlement of due to Harvard Bioscience included in accrued and other current liabilities | $ | — | $ | (750) | ||||
Issuance of Series E convertible preferred stock | $ | — | $ | 4,000 | ||||
Purchases of property and equipment in accounts payable or accrued expenses | $ | 5 | $ | — | ||||
Preferred stock dividends | $ | 77 | $ | 18 | ||||
Conversion of preferred stock into common stock | $ | 4,257 | $ | — |
View original content to download multimedia:https://www.prnewswire.com/news-releases/harvard-apparatus-regenerative-technology-reports-second-quarter-2023-financial-results-301899337.html
SOURCE Harvard Apparatus Regenerative Technology, Inc.
FAQ
What are the financial results of Harvard Apparatus Regenerative Technology for Q2 2023?
Who is the contract research organization for Harvard Apparatus Regenerative Technology's first clinical trial?
What is Harvard Apparatus Regenerative Technology's new business in Hong Kong?
When will Harvard Apparatus Regenerative Technology start selling anti-aging supplements?
What is the current cash and cash equivalents of Harvard Apparatus Regenerative Technology?
How much cash did Harvard Apparatus Regenerative Technology use in operations for the six months ended June 30, 2023?
How much cash did Harvard Apparatus Regenerative Technology receive from financing activities in the six months ended June 30, 2023?